Background
Methods
Patient backgrounds and eligibility
Procedures to examine ER, PgR, HER2, and Ki67
Evaluation of ER, PgR, and HER2 status and Ki67 LI
Statistical analysis
Results
Patient and tumor characteristics
No. of patients | Percent | |
---|---|---|
Total | 177 | 100 |
Menopausal status at diagnosis | ||
Premenopausal | 77 | 43.5 |
Postmenopausal | 100 | 56.5 |
Pathological tumor size | ||
T 1 | 99 | 55.9 |
T 2 | 58 | 32.8 |
T 3 | 10 | 5.6 |
T 4 | 10 | 5.6 |
Pathological nodal status | ||
N 0 | 95 | 53.7 |
N 1 | 46 | 26.0 |
N 2 | 23 | 13.0 |
N 3 | 9 | 5.1 |
Not evaluated | 4 | 2.3 |
Pathological stage | ||
I | 63 | 35.6 |
II A | 55 | 31.1 |
II B | 22 | 12.4 |
III A | 14 | 7.9 |
III B | 10 | 5.6 |
III C | 9 | 5.1 |
Not evaluated | 4 | 2.3 |
Type of surgery | ||
Breast-conserving surgery | 147 | 83.1 |
Mastectomy | 30 | 16.9 |
Axillary management | ||
Sentinel lymph node biopsy alone | 95 | 53.7 |
Axillary lymph node dissection | 79 | 44.6 |
No surgery | 3 | 1.7 |
Histological grade | ||
1 | 41 | 23.2 |
2 | 67 | 37.9 |
3 | 69 | 39.0 |
Adjuvant Chemotherapy | ||
Yes | 70 | 39.5 |
No | 107 | 60.5 |
Adjuvant Endocrine therapy | ||
Yes | 146 | 82.5 |
No | 31 | 17.5 |
No | Percent | |
---|---|---|
Allred Scores of PgR | ||
0 | 21 | 11.8 |
2 | 0 | 0.0 |
3 | 4 | 2.3 |
4 | 12 | 6.8 |
5 | 17 | 9.6 |
6 | 28 | 15.8 |
7 | 42 | 23.7 |
8 | 53 | 29.9 |
Proportion of PgR (%) | ||
0 | 21 | 11.8 |
> 0 and <1 | 4 | 2.3 |
≥ 1 and <10 | 17 | 9.6 |
≥ 10 and <20 | 23 | 13.0 |
≥ 20 and <33 | 10 | 5.6 |
≥ 33 and ≤67 | 48 | 27.1 |
> 67 | 54 | 30.5 |
Ki67 labeling index (%) | ||
≤ 10 | 46 | 26.0 |
> 10 and <14 | 20 | 11.3 |
≥ 14 and <20 | 33 | 18.6 |
≥ 20 an <30 | 45 | 25.4 |
≥ 30 | 33 | 18.6 |
Survival analysis according to the status of PgR
Survival analysis according to Ki67 LI
Relationship between the expression of PgR and Ki67 LI
Relationships between prognosis and clinicopathological characteristics of tumors
RFS | CSS | |||||
---|---|---|---|---|---|---|
Characteristics | HR | 95% CI |
P
| HR | 95% CI |
P
|
PgR expression | ||||||
≥ 20% | Referent | |||||
< 20% | 2.33 | 1.19–4.54 | 0.013 | 5.15 | 2.06–12.85 | 0.00045 |
Ki67 labeling index | ||||||
≤ 10% | Referent | |||||
> 10 and <30% | 0.52 | 0.18–1.53 | 0.24 | 0.28 | 0.05–1.44 | 0.13 |
≥ 30% | 0.69 | 0.33–1.47 | 0.34 | 0.68 | 0.29–1.57 | 0.36 |
Menopausal status | ||||||
Pre- | Referent | |||||
Post- | 1.24 | 0.63–2.43 | 0.53 | 0.72 | 0.33–1.61 | 0.43 |
Pathological T stage | ||||||
T 1–2 | Referent | |||||
T 3–4 | 1.49 | 0.68–3.25 | 0.32 | 1.51 | 0.58–3.90 | 0.40 |
Pathological N stage | ||||||
N 0 | Referent | |||||
N 1–3 | 3.16 | 1.51–6.58 | 0.0022 | 2.69 | 1.04–6.99 | 0.042 |
Histological grade | ||||||
1,2 | Referent | |||||
3 | 1.31 | 0.67–2.56 | 0.43 | 1.40 | 0.60–3.25 | 0.44 |
Adjuvant chemotherapy | ||||||
No | Referent | |||||
Yes | 1.37 | 0.71–2.64 | 0.35 | 1.25 | 0.55–2.82 | 0.59 |
Adjuvant endocrine therapy | ||||||
No | Referent | |||||
Yes | 1.15 | 0.39–3.37 | 0.80 | 1.20 | 0.27–5.42 | 0.81 |